Opendata, web and dolomites

Vacc-iNTS SIGNED

Advancing a GMMA-based vaccine against invasive non-typhoidal salmonellosis through Phase 1 trial in Europe and sub-Saharan Africa

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Vacc-iNTS project word cloud

Explore the words cloud of the Vacc-iNTS project. It provides you a very rough idea of what is the project "Vacc-iNTS" about.

transcriptomics    infectious    lt    olds    adults    drive    saharan    resistance    typhimurium    blebs    african    antibiotic    difficult    experts    antibody    trials    network    ssa    invasive    rapid    biology    generate    epidemiological    membrane    scalable    preclinical    sub    advocate    roadblocks    gmp    enteritidis    gmma    typhoidal    limited    bacteria    sonnei    collaborative    released    resource    proof    poor    genetically    bridges    disease    followed    sero    modules    safety    suited    advancing    20    outer    deployment    cellular    clinical    trial    stage    accelerate    bactericidal    settings    strengthen    integration    data    endemic    advocacy    antigens    generalized    countries    immunogenicity    ints    healthy    animals    profit    fatality    deaths    serotypes    serum    strains    gap    salmonellosis    263    lots    academia    levels    diagnosis    vaccine    immunogenic    proposes    rate    tackling    antibodies    manufacturing    vacc    industry    africa    modified    shigella   

Project "Vacc-iNTS" data sheet

The following table provides information about the project.

Coordinator
SCLAVO VACCINES ASSOCIATION 

Organization address
address: PIAZZA LA LIZZA 7
city: SIENA
postcode: 53100
website: www.sclavo.org/home

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Total cost 0 €
 EC max contribution 6˙871˙188 € (0%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2018-Two-Stage-RTD
 Funding Scheme RIA-LS
 Starting year 2019
 Duration (year-month-day) from 2019-10-01   to  2024-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SCLAVO VACCINES ASSOCIATION IT (SIENA) coordinator 1˙152˙311.00
2    THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD UK (OXFORD) participant 2˙227˙288.00
3    GSK VACCINES INSTITUTE FOR GLOBAL HEALTH SRL IT (SIENA) participant 1˙576˙515.00
4    THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE UK (CAMBRIDGE) participant 545˙942.00
5    THE UNIVERSITY OF LIVERPOOL UK (LIVERPOOL) participant 432˙034.00
6    UNIVERSITA DEGLI STUDI DI SIENA IT (SIENA) participant 341˙017.00
7    KWAME NKRUMAH UNIVERSITY OF SCIENCE AND TECHNOLOGY KUMASI GH (KUMASI) participant 194˙226.00
8    UNIVERSITE OUAGA I PROFESSEUR JOSEPH KI-ZERBO BF (OUAGADOUGOU 03) participant 192˙980.00
9    KENYA MEDICAL RESEARCH INSTITUTE KE (Nairobi) participant 107˙575.00
10    UNIVERSITY OF OTAGO NZ (DUNEDIN) participant 50˙000.00
11    PRINS LEOPOLD INSTITUUT VOOR TROPISCHE GENEESKUNDE BE (ANTWERPEN) participant 31˙296.00
12    MMGH CONSULTING GMBH CH (ZURICH) participant 20˙000.00

Map

 Project objective

Invasive non-typhoidal Salmonellosis (iNTS) is an important emerging Neglected Infectious Disease in resource-poor settings of sub-Saharan Africa (sSA). No vaccine is currently available. Estimated 263,000 iNTS deaths per year in <5 year olds, a 20% case fatality rate, difficult diagnosis and increasing antibiotic resistance strongly advocate for rapid development of an effective vaccine. Vacc-iNTS bridges the gap between preclinical and early clinical development of a novel vaccine against iNTS, based on GMMA (Generalized Modules for Membrane Antigens) from the most common African iNTS serotypes (Typhimurium and Enteritidis). The highly cost-effective GMMA-technology, developed by partner 2, is based on outer membrane blebs released by genetically modified bacteria. Clinical proof-of-concept for the GMMA-technology was achieved with a Shigella sonnei vaccine in European and African adults. In animals, iNTS-GMMA were highly immunogenic and induced antibodies with bactericidal activity against African iNTS strains. Simple, robust and scalable manufacturing processes for iNTS-GMMA, suited for sSA, have been developed. Vacc-iNTS proposes GMP manufacturing of clinical lots followed by a two-stage Phase 1 trial in healthy European and African adults to investigate safety and immunogenicity of the iNTS-GMMA vaccine. Analysis include serum antibody levels and functionality, cellular responses, transcriptomics and data integration through a systems biology approach. Sero-epidemiological analysis will be conducted to provide essential data for future Phase 2 and 3 trials. Vacc-iNTS will also strengthen a collaborative network of iNTS experts from academia, industry and non-profit including partners from disease-endemic countries of sSA. The network will generate data to accelerate further vaccine development, enhance awareness, drive advocacy and vaccine deployment in limited-resources disease-endemic countries, tackling major roadblocks in advancing a vaccine against iNTS.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "VACC-INTS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "VACC-INTS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination

Read More  

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More  

FAIR (2020)

FLAGELLIN AEROSOL THERAPY AS AN IMMUNOMODULATORY ADJUNCT TO THE ANTIBIOTIC TREATMENT OF DRUG-RESISTANT BACTERIAL PNEUMONIA

Read More